| Literature DB >> 33046756 |
Jungchan Park1, Cheol Won Hyeon2, Seung-Hwa Lee3, Sangmin Maria Lee1, Junghyun Yeo1, Kwangmo Yang4, Jeong Jin Min1, Jong Hwan Lee1, Jeong Hoon Yang2, Young Bin Song2, Joo-Yong Hahn2, Seung-Hyuk Choi2, Jin-Ho Choi2,5, Hyeon-Cheol Gwon2.
Abstract
Preoperative high-sensitivity cardiac troponin (hs-cTn) above the 99th-percentile upper reference limit (URL) is associated with mortality after noncardiac surgery. This study aimed to evaluate whether preoperative hs-cTn concentrations above the lowest limit of detection (LOD) but below the 99th-percentile URL can predict mortality after noncardiac surgery.From January 2010 to April 2019, a total of 12,415 noncardiac surgical patients with preoperative hs-cTn I below the 99th-percentile URL were enrolled. The patients were divided into two groups according to preoperative hs-cTn I concentration: (1) [hs-cTn] below the LOD (6 ng/L), and (2) mildly elevated [hs-cTn] but below the 99th-percentile URL (40 ng/L). The primary outcome was 30-day mortality. Of the 12,415 patients enrolled, 7958 (64.1%) were in the LOD group whereas 4457 (35.9%) were in the mild elevation group. The incidence of 30-day mortality was significantly greater in the mild elevation group (2.1% vs. 4.0% hazard ratio [HR] 1.73; 95% confidence interval [CI] 1.39-2.16; p < 0.001) in the multivariate analyses. The propensity score matched analyses also produced a similar result (2.6% vs. 4.2% HR 1.61; 95% CI 1.26-2.07; p < 0.001). The threshold at which the risk of mortality increased corresponded to a preoperative hs-cTn I ≥ 12 ng/L. Patients with preoperative hs-cTn I above the LOD and below the 99th-percentile URL had greater 30-day mortality after noncardiac surgery.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33046756 PMCID: PMC7550329 DOI: 10.1038/s41598-020-72853-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline characteristics.
| Entire population | Propensity score matched population | ||||||
|---|---|---|---|---|---|---|---|
| LOD (N = 7958) | Mild elevation (N = 4457) | p-Value | SMD | LOD (N = 3869) | Mild elevation (N = 3869) | SMD | |
| aPreoperative hs-cTn I, ng/L | 6 | 16 (± 9) | 6 | 16 (± 9) | |||
| Male | 4432 (55.7) | 2603 (58.4) | 0.004 | 5.5 | 2217 (57.3) | 2233 (57.7) | 0.8 |
| Age | 58.0 (± 18.0) | 63.9 (± 17.0) | < 0.001 | 34.2 | 62.6 (± 16.0) | 63.0 (± 17.4) | 2.2 |
| Hypertension | 4417 (55.5) | 3322 (74.5) | < 0.001 | 40.7 | 2722 (70.4) | 2741 (70.8) | 1.1 |
| Diabetes | 1924 (24.2) | 1528 (34.3) | < 0.001 | 22.4 | 1196 (30.9) | 1190 (30.8) | 0.3 |
| Coronary artery disease | 802 (10.1) | 811 (18.2) | < 0.001 | 23.5 | 585 (15.1) | 578 (14.9) | 0.5 |
| Chronic kidney disease | 268 (3.4) | 630 (14.1) | < 0.001 | 38.8 | 264 (6.8) | 264 (6.8) | < 0.1 |
| Previous stroke | 485 (6.1) | 397 (8.9) | < 0.001 | 10.7 | 321 (8.3) | 313 (8.1) | 0.8 |
| Arrhythmia | 339 (4.3) | 452 (10.1) | < 0.001 | 22.9 | 287 (7.4) | 303 (7.8) | 1.6 |
| Current smoking | 663 (8.3) | 310 (7.0) | 0.01 | 5.2 | 271 (7.0) | 284 (7.3) | 1.3 |
| Preoperative hemoglobin, g/dl | 12.5 (± 2.0) | 11.7 (± 2.2) | < 0.001 | 37.8 | 11.9 (± 2.1) | 11.9 (± 2.1) | 0.5 |
| Medication | |||||||
| Antiplatelet agent | 2232 (28.0) | 1921 (43.1) | < 0.001 | 31.8 | 1453 (37.6) | 1474 (38.1) | 1.1 |
| Statin | 2165 (27.2) | 1637 (36.7) | < 0.001 | 20.5 | 1263 (32.6) | 1277 (33.0) | 0.8 |
| Beta-blocker | 1689 (21.2) | 1710 (38.4) | < 0.001 | 38.2 | 1262 (32.6) | 1266 (32.7) | 0.2 |
| Calcium channel blocker | 2586 (32.5) | 2180 (48.9) | < 0.001 | 33.9 | 1725 (44.6) | 1703 (44.0) | 1.1 |
| RAAS inhibitor | 2236 (28.1) | 2001 (44.9) | < 0.001 | 35.4 | 1520 (39.3) | 1520 (39.3) | < 0.1 |
| ESC/ESA surgical risk | < 0.001 | 13 | 7.3 | ||||
| Mild | 2441 (30.7) | 1154 (25.9) | 1112 (28.7) | 1042 (26.9) | |||
| Intermediate | 4554 (57.2) | 2833 (63.6) | 2265 (58.5) | 2397 (62.0) | |||
| High | 963 (12.1) | 470 (10.5) | 492 (12.7) | 430 (11.1) | |||
| Operation type | < 0.001 | 24.9 | 10.4 | ||||
| Vascular | 982 (12.3) | 672 (15.1) | 489 (12.6) | 507 (13.1) | |||
| Orthopedics | 2371 (29.8) | 1378 (30.9) | 1198(31.0) | 1192 (30.8) | |||
| Abdominal | 984 (12.4) | 706 (15.8) | 590 (15.2) | 596 (15.4) | |||
| Thoracic | 22 (0.3) | 8 (0.2) | 7 (0.2) | 8 (0.2) | |||
| Neuro | 2437 (30.6) | 911 (20.4) | 1007 (26.0) | 876 (22.6) | |||
| Otolaryngology, eye | 707 (8.9) | 486 (10.9) | 341 (8.8) | 429 (11.1) | |||
| Urology, gynecology | 455 (5.7) | 296 (6.6) | 237 (6.1) | 261 (6.7) | |||
| Emergency | 1706 (21.4) | 1194 (26.8) | < 0.001 | 12.5 | 1004 (25.9) | 1012 (26.2) | 0.5 |
| General anesthesia | 6449 (81.0) | 3183 (71.4) | < 0.001 | 22.7 | 2902 (75.0) | 2905 (75.1) | 0.2 |
| Operation duration, minute | 161.0 (± 142.1) | 139.9 (± 129.3) | < 0.001 | 157.0 (± 143.6) | 145.2 (± 132.6) | 8.5 | |
| Inotropic drug requirement | 2798 (35.2) | 1751 (39.3) | < 0.001 | 1487 (38.4) | 1511 (39.1) | 1.3 | |
| Red blood cell transfusion | 2978 (37.2) | 1506 (33.8) | < 0.001 | 1374 (35.5) | 1369 (35.4) | 0.3 | |
Data are presented as n (%) or mean (± standard deviation).
LOD limit of detection; hs-cTn high-sensitivity cardiac troponin; RAAS renin–angiotensin–aldosterone system; ESC European Society of Cardiology; ESA European Society of Anaesthesiology.
aPreoperative hs-cTn level and intraoperative variables were not included in propensity score matching.
Clinical outcomes.
| Univariate analysis | Multivariate analysis | Propensity score matched analysis | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| LOD (N = 7958) | Mild elevation (N = 4457) | Unadjusted HR (95% CI) | p-Value | aAdjusted HR (95% CI) | p-Value | LOD (N = 3869) | Mild elevation (N = 3869) | Adjusted HR (95% CI) | p-Value | |
| 30-day mortality | 164 (2.1) | 178 (4.0) | 1.96 (1.58–2.42) | < 0.001 | 1.73 (1.39–2.16) | < 0.001 | 101 (2.6) | 161 (4.2) | 1.61 (1.26–2.07) | < 0.001 |
| In-hospital mortality | 220 (2.8) | 246 (5.5) | 1.59 (1.33–1.91) | < 0.001 | 1.40 (1.16–1.69) | 0.001 | 138 (3.6) | 221 (5.7) | 1.38 (1.12–1.71) | 0.003 |
| 30-day peak hs-cTn I level, ng/L | 242 (± 2862) | 1179 (± 14,520) | < 0.001 | 160 (± 2579) | 688 (± 11,558) | 0.01 | ||||
| MINS | 644 (8.1) | 840 (18.8) | < 0.001 | 385 (10.0) | 684 (17.7) | < 0.001 | ||||
Data are presented as n (%) or mean (± standard deviation).
30-day peak hs-cTn I was available in 4086/7958 (51.3%) in LOD and 2529/4457 (56.7%) in mild elevation groups of the entire population.
30-day peak hs-cTn I was available in 2142/3869 (55.4%) in LOD and 2211/3869 (57.1%) in mild elevation groups of the propensity score matched population.
Patients without elevated postoperative hs-cTn I were regarded as not having been diagnosed with MINS.
LOD limit of detection; HR hazard ration; CI confidential interval; hs-cTn high-sensitivity cardiac troponin; MINS myocardial injury after noncardiac surgery.
aCovariates include age, hypertension, diabetes, coronary artery disease, chronic kidney disease, previous stroke, arrhythmia, preoperative hemoglobin, antiplatelet agent, statin, beta-blocker, calcium channel blocker, renin–angiotensin–aldosterone system inhibitor, surgical risk, operation duration, and intraoperative inotropic use and red cell transfusion.
Figure 1Kaplan–Meier curves for (A) 30-day and (B) in-hospital mortalities of the minimum and minor elevation groups within the full study population, and Kaplan–Meier curves for (C) 30-day and (D) in-hospital mortalities of the minimum and minor elevation groups in the propensity-score-matched population.
Figure 2Kaplan–Meier curves of three groups according to the median preoperative high-sensitivity cardiac troponin I concentrations; (A) 30-day mortality in crude, (B) propensity-score-matched populations and (C) in-hospital mortality in crude, (D) propensity-score-matched populations.
Figure 3(A) Smoothed log-hazard ratio to calculate the threshold for preoperative high-sensitivity cardiac troponin I using a modified Mazumdar approach, (B) Kaplan–Meier curves for 30-day mortality according to the threshold, and (C) Kaplan–Meier curves for in-hospital mortality according to the threshold.
Clinical outcomes according to the calculated threshold of hs-cTn I ≥ 12 ng/L.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Hs-cTn I < 12 ng/L (N = 9647) | Hs-cTn I ≥ 12 ng/L (N = 2768) | Unadjusted HR (95% CI) | p-Value | aAdjusted HR (95% CI) | p-Value | |
| 30-day mortality | 215 (2.2) | 127 (4.6) | 1.88 (1.51–2.33) | < 0.001 | 1.54 (1.23–1.93) | < 0.001 |
| In-hospital mortality | 291 (3.0) | 175 (6.3) | 1.53 (1.28–1.85) | < 0.001 | 1.28 (1.05–1.55) | 0.01 |
| MINS | 853/5007 (17.0) | 631/1608 (39.2) | ||||
Data are presented as n (%) or mean (± standard deviation).
HR hazard ration; CI confidential interval; hs-cTn high-sensitivity cardiac troponin; MINS myocardial injury after noncardiac surgery.
aCovariates include sex, chronic kidney disease, previous stroke, preoperative hemoglobin, statin, beta-blocker, calcium channel blocker, renin–angiotensin–aldosterone system inhibitor, emergency surgery, general anesthesia, operative duration, and intraoperative inotropic use and red cell transfusion.
Clinical outcomes according to the diagnosis of myocardial injury after noncardiac surgery in the entire population.
| Before propensity score matching | After propensity score matching | |||||||
|---|---|---|---|---|---|---|---|---|
| LOD | Mild elevation | LOD | Mild elevation | |||||
| No diagnosed MINS (N = 7314) | Diagnosed MINS (N = 644) | No diagnosed MINS (N = 3617) | Diagnosed MINS (N = 840) | No diagnosed MINS (N = 3484) | Diagnosed MINS (N = 385) | No diagnosed MINS (N = 3185) | Diagnosed MINS (N = 684) | |
| 30-day mortality | 99 (1.4) | 65 (10.1) | 91 (2.5) | 87 (10.4) | 58 (1.7) | 43 (11.2) | 85 (2.7) | 76 (11.1) |
| HR (95%CI) | 1 [Reference] | 7.83 (5.72–10.7) | 1.87 (1.41–2.49) | 8.01 (6.00–10.68) | 1 [Reference] | 7.06 (4.76–10.47) | 1.61 (1.16–2.25) | 6.99 (4.97–9.84) |
| p-Value | < 0.001 | < 0.001 | < 0.001 | < 0.001 | 0.005 | < 0.001 | ||
| In-hospital mortality | 136 (1.9) | 84 (13.0) | 126 (3.5) | 120 (14.3) | 81 (2.3) | 57 (14.8) | 115 (3.6) | 106 (15.5) |
| HR (95%CI) | 1 [Reference] | 3.34 (2.52–4.41) | 1.49 (1.17–1.91) | 4.01 (3.12–5.16) | 1 [Reference] | 3.30 (2.33–4.67) | 1.34 (1.00–1.78) | 3.82 (2.84–5.14) |
| p-Value | < 0.001 | 0.001 | < 0.001 | < 0.001 | 0.05 | < 0.001 | ||
Data are presented as n (%).
30-day peak hs-cTn I was available in 4086/7958 (51.3%) in LOD and 2529/4457 (56.7%) in mild elevation groups of the entire population.
30-day peak hs-cTn I was available in 2142/3869 (55.4%) in LOD and 2211/3869 (57.1%) in mild elevation groups of the propensity score matched population.
LOD limit of detection; HR hazard ration; CI confidential interval; MINS myocardial injury after noncardiac surgery.
Clinical outcomes according to the diagnosis of myocardial injury after noncardiac surgery in patients with postoperative hs-cTn I.
| Before propensity score matching | After propensity score matching | |||||||
|---|---|---|---|---|---|---|---|---|
| LOD | Mild elevation | LOD | Mild elevation | |||||
| No diagnosed MINS (N = 3442) | Diagnosed MINS (N = 644) | No diagnosed MINS (N = 1689) | Diagnosed MINS (N = 840) | No diagnosed MINS (N = 1757) | Diagnosed MINS (N = 385) | No diagnosed MINS (N = 1527) | Diagnosed MINS (N = 684) | |
| 30-day mortality | 52 (154) | 65 (10.1) | 47 (2.8) | 87 (10.4) | 29 (1.7) | 43 (11.2) | 44 (2.9) | 76 (11.1) |
| HR (95%CI) | 1 [Reference] | 6.99 (4.86–10.07) | 1.86 (1.25–2.76) | 7.16 (5.08–10.10) | 1 [Reference] | 7.11 (4.44–11.38) | 1.76 (1.10–2.81) | 7.05 (4.59–10.81) |
| p-Value | < 0.001 | 0.002 | < 0.001 | < 0.001 | 0.02 | < 0.001 | ||
| In-hospital mortality | 77 (2.2) | 84 (13.0) | 66 (3.9) | 120 (14.3) | 46 (2.6) | 57 (14.8) | 61 (4.0) | 106 (15.5) |
| HR (95%CI) | 1 [Reference] | 2.59 (1.88–3.56) | 1.36 (0.98–1.90) | 3.12 (2.32–4.17) | 1 [Reference] | 2.61 (1.75–3.90) | 1.25 (0.85–1.84) | 3.03 (2.13–4.31) |
| p-Value | < 0.001 | 0.07 | < 0.001 | < 0.001 | 0.25 | < 0.001 | ||
Data are presented as n (%).
LOD limit of detection; HR hazard ration; CI confidential interval; hs-cTn high-sensitivity cardiac troponin; MINS myocardial injury after noncardiac surgery.
Figure 4Kaplan–Meier curves for 30-day mortality according to diagnosed MINS; (A) crude and (B) propensity-score-matched population.